ATE503484T1 - Verfahren zur herstellung fester dispersionen von midostaurin - Google Patents

Verfahren zur herstellung fester dispersionen von midostaurin

Info

Publication number
ATE503484T1
ATE503484T1 AT07811314T AT07811314T ATE503484T1 AT E503484 T1 ATE503484 T1 AT E503484T1 AT 07811314 T AT07811314 T AT 07811314T AT 07811314 T AT07811314 T AT 07811314T AT E503484 T1 ATE503484 T1 AT E503484T1
Authority
AT
Austria
Prior art keywords
solid dispersions
midostaurin
producing solid
highly crystalline
compounds
Prior art date
Application number
AT07811314T
Other languages
English (en)
Inventor
Indrajit Ghosh
Jennifer Snyder
Wei-Qin Tong
Sudha Vippagunta
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE503484T1 publication Critical patent/ATE503484T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
  • Glass Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
AT07811314T 2006-08-16 2007-08-14 Verfahren zur herstellung fester dispersionen von midostaurin ATE503484T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82255606P 2006-08-16 2006-08-16
PCT/US2007/017960 WO2008021347A2 (en) 2006-08-16 2007-08-14 Method for making solid dispersions of highly crystalline therapeutic compounds

Publications (1)

Publication Number Publication Date
ATE503484T1 true ATE503484T1 (de) 2011-04-15

Family

ID=38657762

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07811314T ATE503484T1 (de) 2006-08-16 2007-08-14 Verfahren zur herstellung fester dispersionen von midostaurin

Country Status (16)

Country Link
US (2) US20100038816A1 (de)
EP (1) EP2054040B1 (de)
JP (1) JP5546860B2 (de)
KR (1) KR101462693B1 (de)
CN (1) CN101516339B (de)
AT (1) ATE503484T1 (de)
AU (1) AU2007284615B2 (de)
BR (1) BRPI0714963A2 (de)
CA (1) CA2660086C (de)
DE (1) DE602007013567D1 (de)
ES (1) ES2363725T3 (de)
MX (1) MX2009001636A (de)
PL (1) PL2054040T3 (de)
PT (1) PT2054040E (de)
RU (1) RU2454220C2 (de)
WO (1) WO2008021347A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1923053A1 (de) 2006-09-27 2008-05-21 Novartis AG Pharmazeutische Zusammensetzung umfassend Nilotinib oder dessen Salz
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
MX2010011962A (es) * 2008-04-30 2010-11-30 Novartis Ag Proceso continuo para hacer composiciones farmaceuticas.
EP2327706A1 (de) 2009-11-30 2011-06-01 Novartis AG Polymorphe Formen III und IV von N-Benzoyl-Staurosporin
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CN102525879B (zh) * 2010-12-31 2015-01-21 正大天晴药业集团股份有限公司 制备阿瑞匹坦固体分散组合物的方法
EP3122799B8 (de) 2014-03-25 2020-03-11 F.Hoffmann-La Roche Ag Verfahren zur herstellung von poloxamer zur verwendung bei zellkulturmedium
CN107001322B (zh) 2014-12-18 2020-07-28 默沙东公司 用于药物制剂的组合物
GB201502073D0 (en) * 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd HDEG technology
ES2758300T3 (es) 2015-08-20 2020-05-05 Unilever Nv Solubilidad de lactama mejorada
WO2017029093A1 (en) 2015-08-20 2017-02-23 Unilever Plc Improved lactam solubility
BR112018003074B1 (pt) 2015-08-20 2021-07-13 Unilever Ip Holdings B.V. Composição compreendendo uma lactama e um biotensoativo de glicolipídeo
EP3337448A1 (de) * 2015-08-20 2018-06-27 Unilever PLC, a company registered in England and Wales under company no. 41424 of Dispergierte lactame
CN108024939B (zh) 2015-08-20 2024-06-07 联合利华知识产权控股有限公司 包封的内酰胺
CN107848968B (zh) 2015-08-20 2021-06-18 荷兰联合利华有限公司 从乙醛酸制备内酰胺的方法
BR112018002983B1 (pt) 2015-08-20 2021-06-29 Unilever Ip Holdings B.V. Composição compreendendo uma lactama e um álcool
WO2017163072A1 (en) * 2016-03-24 2017-09-28 Locate Therapeutics Limited Scaffolding material, methods and uses
EP3454836A1 (de) * 2016-05-13 2019-03-20 Merck Patent GmbH Heissschmelzextrusionszusammensetzung mit einem direkt komprimierbaren hilfsstoff als weichmacher
JP2021512860A (ja) 2018-02-01 2021-05-20 コーバス・ファーマシューティカルズ・インコーポレイテッド 薬学的製剤
EP3520782A3 (de) * 2018-02-01 2019-11-13 Corvus Pharmaceuticals, Inc. Pharmazeutische formulierungen mit adenosine a2a rezeptor antagonisten
CN113573712A (zh) 2019-02-18 2021-10-29 斯莱班克制药有限责任公司 尼洛替尼的药物组合物
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
JP2024516108A (ja) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術
CN114796149A (zh) * 2022-04-27 2022-07-29 苏州中化药品工业有限公司 一种高生物利用度的双醋瑞因胶囊剂及其制备方法
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US5837714A (en) * 1997-03-03 1998-11-17 Sanofi Solid pharmaceutical dispersions
WO1999021534A1 (en) 1997-10-27 1999-05-06 Merck Patent Gmbh Solid state solutions and dispersions of poorly water soluble drugs
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
DE60211494T2 (de) * 2001-03-26 2006-10-12 Novartis Ag Pharmazeutische zusammensetzung enthaltend ein schlecht wasserlösliches staurosporin, eine oberflächenaktive substanz und ein wasserlösliches polymer
PT1390063E (pt) * 2001-05-03 2005-03-31 Hoffmann La Roche Forma de dosagem farmaceutica de mesilato de nelfinavir amorfo
US20030212102A1 (en) * 2001-06-12 2003-11-13 Koretke Todd W Novel solid dispersion compositions
JP4644397B2 (ja) * 2001-09-05 2011-03-02 信越化学工業株式会社 難溶性薬物を含む医薬用固形製剤の製造方法
US7049322B2 (en) * 2002-02-21 2006-05-23 Supergen, Inc. Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
GB0315012D0 (en) * 2003-06-27 2003-07-30 Leuven K U Res & Dev Zeotiles
US20050080075A1 (en) * 2003-08-25 2005-04-14 Nichols M. James Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
WO2005051368A2 (en) * 2003-11-21 2005-06-09 Schering Corporation Phosphodiesterase v inhibitor formulations
WO2005053727A2 (en) * 2003-11-29 2005-06-16 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
EA013427B1 (ru) * 2004-03-15 2010-04-30 Такеда Фармасьютикал Компани Лимитед Ингибиторы дипептидилпептидазы
US20050288481A1 (en) * 2004-04-30 2005-12-29 Desnoyer Jessica R Design of poly(ester amides) for the control of agent-release from polymeric compositions
US20060246109A1 (en) * 2005-04-29 2006-11-02 Hossainy Syed F Concentration gradient profiles for control of agent release rates from polymer matrices
RU2410098C2 (ru) * 2004-08-31 2011-01-27 Новартис Аг Применение мидостаурина для лечения желудочно-кишечных стромальных опухолей
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
JO2897B1 (en) * 2004-11-05 2015-09-15 نوفارتيس ايه جي Organic compounds
CA2589537A1 (en) * 2004-12-02 2006-06-08 Stephen Craig Dyar Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
ATE482690T1 (de) * 2005-12-14 2010-10-15 Hoffmann La Roche Hcv-prodrug-formulierung
PL2526933T3 (pl) * 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
US8258137B2 (en) * 2008-01-29 2012-09-04 Katholieke Universiteit Leuven Process for release of biologically active species from mesoporous oxide systems
RU2011140486A (ru) * 2009-03-06 2013-04-20 МЕДИММЬЮН, ЭлЭлСи Композиции, содержащие гуманизированные антитела к cd19
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
EP2327706A1 (de) * 2009-11-30 2011-06-01 Novartis AG Polymorphe Formen III und IV von N-Benzoyl-Staurosporin
NZ772688A (en) * 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
WO2012040524A1 (en) * 2010-09-24 2012-03-29 Mallinckrodt Llc Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers
JP6130305B2 (ja) * 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用

Also Published As

Publication number Publication date
RU2454220C2 (ru) 2012-06-27
RU2009109357A (ru) 2010-09-27
US8641948B2 (en) 2014-02-04
US20120190667A1 (en) 2012-07-26
CN101516339A (zh) 2009-08-26
KR20090042961A (ko) 2009-05-04
MX2009001636A (es) 2009-02-23
US20100038816A1 (en) 2010-02-18
PL2054040T3 (pl) 2011-09-30
DE602007013567D1 (de) 2011-05-12
WO2008021347A3 (en) 2008-08-07
CA2660086C (en) 2014-09-16
AU2007284615B2 (en) 2011-10-27
CN101516339B (zh) 2012-06-13
PT2054040E (pt) 2011-06-30
KR101462693B1 (ko) 2014-11-17
WO2008021347A2 (en) 2008-02-21
ES2363725T3 (es) 2011-08-12
EP2054040A2 (de) 2009-05-06
EP2054040B1 (de) 2011-03-30
CA2660086A1 (en) 2008-02-21
JP2010500411A (ja) 2010-01-07
BRPI0714963A2 (pt) 2013-07-30
JP5546860B2 (ja) 2014-07-09
AU2007284615A1 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
DE602007013567D1 (de) Verfahren zur herstellung fester dispersionen von midostaurin
ATE482966T1 (de) Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
DE602006009192D1 (de) Verfahren zur Herstellung von Dünnschichttransistoren mit Top-Gate-Geometrie
DE602005000951D1 (de) Verfahren zur Herstellung von mit Kohlenstoff Nanoröhren verstärkten Verbundwerkstoffen
ATE430480T1 (de) Verfahren zur herstellung von nährmittelzusammensetzungen
ATE492547T1 (de) Verfahren zur herstellung lipophiler pharmazeutisch akzeptabler salze aus pemetrexed- disäure
AR058519A1 (es) Particulas que interrumpen o impiden la adhesion bacteriana composiciones y metodos relacionados
ATE477799T1 (de) Substituierte pyrazolopyridine, diese enthaltende zusammensetzungen, verfahren zur herstellung davon sowie deren verwendung
DE602005024206D1 (de) Verfahren zur Herstellung von hydrophilen Kohlenstoffnanoröhren
ATE517094T1 (de) Verfahren zur herstellung von medetomidin und seinen salzen
ATE465990T1 (de) Arylalkylcarbamatderivate, verfahren zur ihrer herstellung und deren therapeutischen anwendungen
EP1947705A4 (de) Lichtquelle und verfahren zur herstellung derselben
ATE461266T1 (de) Zusammensetzung mit verbesserter stabilität und verfahren zu ihrer herstellung
DE502006001281D1 (de) Verfahren zur herstellung substituierter biphenyle
DE602005007734D1 (de) Verfahren zur herstellung von telmisartan
ATE486841T1 (de) Verfahren zur herstellung von pregabalin und salzen daraus
ATE430140T1 (de) Verfahren zur herstellung von ä1,4,5ü- oxadiazepinderivaten
ATE528301T1 (de) Verfahren zur herstellung von substituierten sulfoxidzusammensetzungen
DE502004007560D1 (de) Bipolartransistor und verfahren zur herstellung desselben
EP1845941A4 (de) Sirupzusammensetzung mit dexibupropen als aktivem bestandteil und verfahren zur herstellung davon
EP1870457A4 (de) Dipeptidkristall und verfahren zur herstellung davon
ATE459537T1 (de) Verfahren zur herstellung von blistern, streifen, beuteln, ampullenhaltern und dergleichen
DE502005003679D1 (de) Vorrichtung zur potentialtrennung, ringkerndrossel und verfahren zur herstellung der ringkerndrossel
EP1851324A4 (de) Neuartige proteine mit erweiterter funktionalität und verfahren zur herstellung neuartiger proteine durch zirkuläre permutation
DE602004005442D1 (de) Emitter für eine Ionenquelle und Verfahren zur dessen Herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2054040

Country of ref document: EP